99 related articles for article (PubMed ID: 17595760)
1. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
Watanabe Y; Ueda H; Etoh T; Koike E; Fujinami N; Mitsuhashi A; Hoshiai H
Anticancer Res; 2007; 27(3B):1449-52. PubMed ID: 17595760
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
[TBL] [Abstract][Full Text] [Related]
3. [Methylation of hMLH1 gene promoter in gastric carcinoma with microsatellite instability].
Li JH; Shi XZ; Liu M; Wang Y; Yu ZH; Xu GW; Lu S
Ai Zheng; 2005 Mar; 24(3):273-7. PubMed ID: 15757526
[TBL] [Abstract][Full Text] [Related]
4. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
6. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.
Gifford G; Paul J; Vasey PA; Kaye SB; Brown R
Clin Cancer Res; 2004 Jul; 10(13):4420-6. PubMed ID: 15240532
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma.
Tzao C; Hsu HS; Sun GH; Lai HL; Wang YC; Tung HJ; Yu CP; Cheng YL; Lee SC
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1371. PubMed ID: 16256791
[TBL] [Abstract][Full Text] [Related]
8. [Hypermethylation of hMLH1 and microsatellite instability in ovarian mucinous tumors].
Chen HZ; Ye DF; Xie X; Hu M; Lu WG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):457-61. PubMed ID: 12974095
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype.
Sengupta S; Chakrabarti S; Roy A; Panda CK; Roychoudhury S
Cancer; 2007 Feb; 109(4):703-12. PubMed ID: 17219447
[TBL] [Abstract][Full Text] [Related]
10. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
11. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
12. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
13. Defective mismatch repair and the development of recurrent endometrial carcinoma.
Pijnenborg JM; Dam-de Veen GC; de Haan J; van Engeland M; Groothuis PG
Gynecol Oncol; 2004 Aug; 94(2):550-9. PubMed ID: 15297202
[TBL] [Abstract][Full Text] [Related]
14. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
[TBL] [Abstract][Full Text] [Related]
15. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).
Chaudhry P; Srinivasan R; Patel FD
Cancer Invest; 2009 Oct; 27(8):877-84. PubMed ID: 19548140
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.
Wang YC; Lu YP; Tseng RC; Lin RK; Chang JW; Chen JT; Shih CM; Chen CY
J Clin Invest; 2003 Mar; 111(6):887-95. PubMed ID: 12639995
[TBL] [Abstract][Full Text] [Related]
17. Frequent hypermethylation of the hMLH1 gene promoter in differentiated-type tumors of the stomach with the gastric foveolar phenotype.
Endoh Y; Tamura G; Ajioka Y; Watanabe H; Motoyama T
Am J Pathol; 2000 Sep; 157(3):717-22. PubMed ID: 10980110
[TBL] [Abstract][Full Text] [Related]
18. High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas.
Strazzullo M; Cossu A; Baldinu P; Colombino M; Satta MP; Tanda F; De Bonis ML; Cerase A; D'Urso M; D'Esposito M; Palmieri G
Cancer; 2003 Oct; 98(7):1540-6. PubMed ID: 14508843
[TBL] [Abstract][Full Text] [Related]
19. The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer.
Wang J; Yu L; Cai J; Jia J; Gao Y; Liang M; Wang Z
Biochem Biophys Res Commun; 2013 Apr; 433(4):470-6. PubMed ID: 23523787
[TBL] [Abstract][Full Text] [Related]
20. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
